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Objective: Most endometrial carcinomas appear to develop from precursors (e.g., endometrial hyper-
plasia) that progress for several years. Patients who are ultimately diagnosed with carcinoma often
present clinically with complaints of abnormal vaginal bleeding years before diagnosis, which offers an
opportunity for early diagnosis and curative treatment. The analysis of DNA methylation may be used as
a method for detecting endometrial cancer (EC). To test the potential clinical application of this method,
we used quantitative methylation analysis of ﬁve genes in a full spectrum of endometrial lesions.
Materials and methods: This hospital-based, prospective, case-controlled study was conducted on 68
patients, which included patients who had a normal endometrium (n ¼ 18), hyperplasia of the endo-
metrium (n ¼ 24), and EC (n ¼ 26). Methylation levels of the following genes were determined by using
real-time methylation-speciﬁc polymerase chain reaction (PCR) ampliﬁcation: zinc ﬁnger protein 177
(ZNF177), collagen type XIV a1 (COL14A1), dihydropyrimidinase-like 4 (DPYSL4), homeobox A9 (HOXA9),
transmembrane protein with epidermal growth factor-like and two follistatin-like domains 2 (TMEFF2).
The methylation index (MI) cutoff values for the different diagnoses were determined to test the
sensitivity and speciﬁcity of the method and to generate the receiver operating characteristic (ROC)
curves. The ManneWhitney U test was used to test between-group differences in the MI.
Results: The MI of the ﬁve genes was signiﬁcantly higher in EC than the MIs in specimens of hyperplasia
of endometrium and normal appearance (p < 0.001). The ROC analysis demonstrated that the sensitivity,
speciﬁcity, and accuracy for detecting EC were 92.3%, 94.4%, and 95.1%, respectively, for ZNF177; 92.3%,
94.4%, and 95.7%, respectively, for COL14A1; 80.8%, 94.4%, and 81.4%, respectively, for HOXA9; 65.4%,
94.4%, and 89.5%, respectively, for TMEFF2; and 61.5%, 94.4%, and 63.3%, respectively, for DPYSL4. The
combined testing of ZNF177 and COL14A1 had the best speciﬁcity (100%), but compromised sensitivity
(88.5%).
Conclusion: Promoter methylation of ZNF177, COL14A1, HOXA9, DPYSL4, and TMEFF2 genes is a frequent
epigenetic event in EC. Furthermore, the epigenetic hypermethylation of TMEFF2 may be a valuable
marker for identifying undetected EC within endometrial hyperplasia.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.nd Gynecology, Tri-Service General Hospital, National Defense Medical Center, 5F, 325, Section 2, Cheng-Gong Road,
bstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Endometrial cancer (EC) is a very common gynecological ma-
lignancy, and its frequency is increasing in the developed world; it
is the fourth most common cancer in women in Europe. However,
its mortality rate is the lowest among all gynecological malig-
nancies (20e24/100,000 women), which indicates a good prog-
nostic outcome when it is detected early [1,2]. Endometrial cancer
is conventionally classiﬁed into two types. Type I is associated with
an endocrine milieu of estrogen predominance and develops from
endometrial hyperplasia. The tumor is positive for the estrogen
receptor and progesterone receptor, shows well-differentiated
endometrioid adenocarcinoma, has a lower frequency of lymph
node metastasis, shows little muscular invasion, and often has a
relatively more favorable prognosis than Type 2 cancer [3e5]. By
contrast, Type 2 EC tends to develop in postmenopausal women in
an estrogen-independent manner, and may result from de novo
carcinogenesis that develops directly from the normal endome-
trium, rather than via endometrial hyperplasia or undiagnosed
precancerous lesions. Type 2 cancer is the aggressive histological
subtype of EC and represents less than 10% of all ECs, but accounts
for more than 50% of recurrences and deaths attributable to EC [6].
The transition from a normal endometrium to a malignant tumor
may involve a stepwise accumulation of alterations in cellular
mechanisms leading to dysfunctional cell growth [7].
Like many cancers, EC is a complex disease affected by genetic,
epigenetic, and environmental factors. One type of epigenetic
modiﬁcation is DNA methylation. Aberrant hypermethylation of
cytosine-phosphate-guanine (CpG) islands present in the pro-
moters of genes is associated with gene silencing. Tumorigenesis
may be initiated by the epigenetic silencing of genes belonging to
different classes of activity such as cell-cycle control, detoxiﬁcation,
differentiation, DNA repair, signal transduction, and apoptosis [8,9].
An overall reduction in the total 5-methylcytosine level and focal
hypermethylation in CpG islands near the tumor-suppressor gene
transcriptional start sites occur in many different types of cancers,
including EC [10].
Most ECs appear to develop from precursors, termed “endo-
metrial hyperplasia,”which progress for several years. Patients who
are ultimately diagnosed with EC often present clinically with
complaints of abnormal vaginal bleeding years before diagnosis,
which offers an opportunity for early diagnosis and curative
treatment [11]. However, many such patients undergo repeated
evaluations, inconvenience, and stress because abnormal vaginal
bleeding is an extremely common complaint that is unrelated to EC
in a substantial number of women [12]. Thus, it may be challenging
to distinguish the minority of womenwho requiremanagement for
carcinoma precursors or carcinoma from women with benign
causes of abnormal bleeding. It is important to discover the hidden
lesions of carcinoma precursors in the endometrium.
In the current study, we used the Illumina Methylation 450K
array (Illumina, San Diego, CA, USA) to analyze the global methyl-
ation proﬁling of EC and normal endometrial tissue in patients with
cancer versus endometrial tissue from healthy individuals. After
analysis of the methylation differences in combination with inde-
pendent gene expression data, a set of genes that are deregulated
by aberrant DNAmethylation in EC was identiﬁed. We then focused
on ﬁve genes with aberrant DNA methylation, which included the
genes for zinc ﬁnger protein 177 (ZNF177), collagen type XIV a1
(COL14A1), dihydropyrimidinase-like 4 (DPYSL4), homeobox A9
(HOXA9), and transmembrane protein with epidermal growth
factor-like and two follistatin-like domains 2 (TMEFF2). We used a
quantitative methylation polymerase chain reaction (qMSP) with
validation analysis using additional EC tissues, tissues with hyper-
plasia of the endometrium, and tissues from normal controls.Materials and methods
Tissue collection
This was a prospective study that initially enrolled 68 partici-
pants who were referred to the Department of Obstetrics and Gy-
necology at the Tri-Service General Hospital of the National
Defense Medical Center (Taipei, Taiwan). The study included
women who had endometrioid-type EC (n ¼ 26; 6 G1 cases, 9 G2
cases, 11 G3 cases). Endometrial biopsy of tissues of patients with
hyperplasia (n¼ 24) andwith a normal endometrium (n¼ 18) were
collected for methylation analysis. All patients underwent a hys-
terectomy within 3 months of endometrial biopsy. The ﬁnal diag-
nosis was based on the worst pathologic ﬁnding from the
endometrial sampling or hysterectomy. Exclusion criteria were
womenwho had a history of previous endometrial surgery, history
of a previous gynecological malignancy, synchronous malignancy,
and patients with an endometrial malignancy other than endo-
metrioid adenocarcinoma (e.g., serous or clear cell type). The
endometrial biopsies underwent immediate processing for DNA
extraction or were fresh frozen and stored at 80C.
Ethics approval
The study was approved by the ethics committee of the Insti-
tutional Review Board of the Tri-Service General Hospital (Taipei,
Taiwan). Informed consent was obtained from all patients and
control participants.
Genomic DNA extraction
Genomic DNA was extracted from tissue samples using the
commercial DNA extraction kit QIAmp Tissue Kit (Qiagen, Hilden,
Germany). Tumor DNA was prepared as described previously [8].
Bisulﬁte conversion
The DNA from the tumor specimens was subjected to bisulﬁte
methylation analysis. We treated DNA with bisulﬁte using the EZ
DNA Methylation Kit (Zymo Research, Orange, CA, USA), as
described previously [13]. In brief, 1 mg of genomic DNA was de-
natured by incubation with 0.2M sodium hydroxide (NaOH). Ali-
quots of 10mM hydroquinone and 3M sodium bisulﬁte (pH 5.0)
were added, and the solution was incubated at 50C for 16 hours.
The treated DNA was puriﬁed on a Zymo-Spin I column (Zymo
Research), desulfonated with 0.3M NaOH, repuriﬁed on a Zymo-
Spin I column, and resuspended in 20 mL elution buffer. After the
bisulﬁte treatment, all DNA samples were stored at 80C [13].
Methylation-speciﬁc polymerase chain reaction
Methylation-speciﬁc polymerase chain reaction (MS-PCR) was
conducted in a total volume of 20 mL, which contained 0.8 mL of
2.5mM primers, 1 mL of the sodium bisulﬁte-treated DNA, and 10 mL
of 2 RBC SensiZyme HotStart Taq Mastermix (RBC Bioscience
Corp, Taipei, Taiwan). The primers for MS-PCR were designed to
detect methylated sequences. Their options were the most G-C-rich
regions closest to the transcription start site. Methylation of these
regions of CpG islands is associated with transcriptional silencing.
Table 1 summarizes the characteristics of theMS-PCR reactions and
the primer sequence for each gene. The PCR products were
analyzed by electrophoresis on 2.5% agarose gels and visualized
after staining with ethidium bromide. All MS-PCR data were ob-
tained from at least three independent modiﬁcations of DNA to
ensure reproducibility [8,13].
Table 2
The patients' characteristics.
Histopathology Age (y),
mean ± SD
BMI
(mean ± SD)
Normal endometrium 45.5 ± 3.4 24.3 ± 3.2
Hyperplasia of
endometrium
50.1 ± 3.9a 23.4 ± 3.0
Endometrial cancer 61.5 ± 8.3b 25.9 ± 6.4
BMI ¼ body mass index; SD ¼ standard deviation.
a The difference between hyperplasia of the endometrium and a normal endo-
metrium, as determined by the independent sample Student t test (p ¼ 0.0003).
b The difference between endometrial cancer and hyperplasia of the endome-
trium, as determined by the independent sample Student t test (p < 0.0001).
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SYBR Green-based quantitative methylation polymerase chain
reaction (qMSP; SuperArray Bioscience, Frederick, USA) was per-
formed after the bisulﬁte treatment on the denatured genomic
DNA. The primers and probes for each gene were ZNF177, COL14A1,
HOXA9, and TMEFF2 (the sequences will be provided on request).
The gene for the collagen type II a1 gene (COL2A) was used as the
internal reference gene by amplifying non-CpG sequences. Each
sample was analyzed in duplicate.
To generate a positive control and a negative control for MSP/
qMSP, the CpG methylated human genomic DNA (Thermo Fisher
Scientiﬁc, Waltham, USA) and DNA from normal peripheral blood
lymphocytes were modiﬁed by sodium bisulﬁte. The SYBR Green-
based qMSP method was used to determine the methylation level
of each gene in the tissue samples. We used COL2A as an internal
reference gene by amplifying the non-CpG sequences. Quantitative
methylation polymerase chain reaction was conducted in a total
volume of 20 mL that contained 1 mL of 10mM primers, 2 mL of
bisulfate-treated DNA, and 10 mL of RT2 SYBR green qPCR Master-
mix (Qiagen, Hilden, Germany). The reactions were detected using
a LightCycler 480 Real-Time PCR system (Roche, Basel,
Switzerland). Each sample was analyzed in triplicate. Test results
with a quantiﬁcation cycle (Cq) value of COL2A >38 were deﬁned as
a detection failure. After PCR analysis, results with a Cq value of the
target gene >45 were deﬁned as undetermined. The DNA methyl-
ation level was assessed as the methylation index (MI) by using the
formula: 100  2[(Cq of COL2A) e (Cq of gene)] [14].
Statistical analysis
The age and body mass index (BMI) differences between the
controls and the patients were compared using independent
sample Student t tests. The differences in DNA methylation be-
tween the three groups were analyzed by the Chi-square test or by
the Fisher's exact test. ManneWhitney U tests were used to test
differences in MI between groups. Receiver operating character-
istic (ROC) curves were generated to conﬁrm the accuracy of
diagnosis for each gene, and the sensitivity and speciﬁcity were
computed for each combination. Each group was required to
achieve an adequate power (0.90) with a level <0.05 to test for a
0.35 difference in the area under the ROC curve from 0.5 (i.e., a
straight line from bottom left to top right corners, which implies a
decision rule that is no better than pure chance). All differences
were considered statistically signiﬁcant at p < 0.05. All analyses
were performed using IBM SPSS Statistics software, version 22
(IBM Corp, Armonk, USA).Table 1
The primer list of the tested genes and the characteristics of methylation-speciﬁc polym
Gene name Sense
ZNF177 M GGAAGTGGGCGTTCGTCGTTTC
U TGGAAGTGGGTGTTTGTTGTTTTGTTA
COL14A1 M TTTTCGTTTTATAATTGGTTGTCGGC
U TTTTTTGTTTTATAATTGGTTGTTGGTG
HOXA9 M CGGGCGTTTTTCGTTTTAGGC
U TTGGGTGTTTTTTGTTTTAGGTGGG
TMEFF2 M AGGAGAGGGATTTAAATTTGCGAAC
U GAGGAGAGGGATTTAAATTTGTGAAT
DPYSL4 M CGTTTCGGTTTTTGGGGAGC
U TGTGTTTTGGTTTTTGGGGAGTG
COL2A GGGAAGATGGGATAGAAGGGAATAT
COL14A1¼ collagen type XIV a1;DPYSL4¼ dihydropyrimidinase-like 4;HOXA9¼ homeob
follistatin-like domains 2; ZNF177 ¼ zinc ﬁnger protein 177.Results
Table 2 shows the characteristics of the enrolled patients. The
mean patient age increased in accordance with disease severity
(p < 0.001), which was expected. Quantitative assessment of DNA
methylation for each gene, based on disease severity, is shown in
Figure 1 and Table 3. The medianMI was low in tissue samples from
the normal endometrium for all genes (5.6%). The median MI was
increased in tissue samples with endometrial hyperplasia for all
genes (16.7% for ZNF177, 33.3% for COL14A1, 20.8% forHOXA9, 50% for
TMEFF2, and 8.3% forDPYSL4). There are signiﬁcant differences of the
median MI in TMEFF2 between the normal endometrium and endo-
metrial hyperplasia. In patients with EC, the methylation rates were
92.3% for ZNF177, 92.3% for COL12A1, 80.8% for HOXA9, 65.4% for
TMEFF2, and 61.5% for DPYSL4. These values differed signiﬁcantly
from the values in patients with endometrial hyperplasia (16.7%,
33.3%, 20.8%, 50%, and 8.3%, respectively) or with a normal endo-
metrium (5.6%, 5.6%, 5.6%, 5.6%, and 5.6%, respectively; for all com-
parisons between the 3 groups, p < 0.001). To validate the results of
qMSP, MS-PCR and its product sequencing were performed with
random sampling of EC, hyperplasia of endometrium, and normal
controls. The results are shown in Figures 2 and 3. The trends of
methylationstatusofMS-PCRare consistentwith the results of qMSP.
The result of the sequencing of the MS-PCR product was validated.
To assess the clinical application of the method, the ROC curves
were generated, and the areas under the ROC curvewere calculated
to discriminate between the normal endometrium and the EC
group (Figure 4). The sensitivity and speciﬁcity were calculated by
the best cutoff MI values for each gene (Figure 4). The sensitivity
ranged from 61.5% to 92.3% and speciﬁcity was 94.4% for the normal
endometrium group, and the sensitivity and speciﬁcity were both
94.4% for the EC group. The COL14A1 gene conferred the best per-
formance for the detection of EC with a sensitivity, speciﬁcity, anderase chain reaction.
Antisense Tm
(C)
CCCTTCCCTCCCGATTCCG 60
CTTCCCTCCCAATTCCACCAACC 60
CCCTCTCCTTCTACCGCTACGCT 60
GG CTCCCTCTCCTTCTACCACTACA 60
AAATCCGTCCCAAACGAAACCG 60
AAAAATCAAATTCAACACAAAATCCATC 62
CGAAACAACTCAACCATCCCGAC 60
G CCAAAACAACTCAACCATCCCAAC 60
CCGAACCAAAATCCGAACGC 60
CAAACCAAAATCCAAACACCAAACTAT 60
TCTAACAATTATAAACTCCAACCACCAA 58
ox A9; TMEFF2¼ transmembrane protein with epidermal growth factor-like and two
Figure 1. The methylation index (MI) values for the genes ZNF177, COL14A1, DPYSL4, HOXA9, and TMEFF2, as determined from scrapings of the normal endometrium and tissues of
endometrial hyperplasia, and endometrial cancer. They are presented according to histology. Each round, square, or triangle black mark represents the test results of one patient.
* p < 0.05, ** p < 0.01, and *** p < 0.001; based on the ManneWhitney U test. COL14A1 ¼ collagen type XIV a1; DPYSL4 ¼ dihydropyrimidinase-like 4; HOXA9 ¼ homeobox A9;
TMEFF2 ¼ transmembrane protein with epidermal growth factor-like and two follistatin-like domains 2; ZNF177 ¼ zinc ﬁnger protein 177.
Y.-C. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 572e579 575accuracy of 92.3%, 94.4%, and 95.7%, respectively. The performance
of combined testing was also calculated (Table 4). Combined testing
of either ZNF177 or COL14A1 had greater sensitivity (92.3%) and
compromised speciﬁcity (94.4%). Combined testing of both ZNF177Table 3
The methylation index (MI) for each gene, according to disease severity.
Gene The nu
Normal endometrium
(n ¼ 18), n (%)
ZNF177 1/18 (5.6)
COL14A1 1/18 (5.6)
HOXA9 1/18 (5.6)
TMEFF2 1/18 (5.6)
DPYSL4 1/18 (5.6)
COL14A1 ¼ collagen type XIV a1; DPYSL4 ¼ dihydropyrimidinase-like 4; HOXA9 ¼ home
two follistatin-like domains 2; ZNF177 ¼ zinc ﬁnger protein 177.
a The value of the comparisons between the three groups (p < 0.001). All results haveand COL14A1 also had greater speciﬁcity (100%) and compromised
sensitivity (88.5%). The relationship between the clinicopatholog-
ical parameters and DNA methylation patterns in the test group
patients was explored.mber of methylated samples/total (%)
Hyperplasia of the endometrium
(n ¼ 24), n (%)
Endometrial cancer
(n ¼ 26), n (%)
4/24 (16.7) 24/26 (92.3)a
8/24 (33.3) 24/26 (92.3)a
5/24 (20.8) 21/27 (80.8)a
12/24 (50) 17/26 (65.4)a
2/24 (8.3) 16/26 (61.5)a
obox A9; TMEFF2 ¼ transmembrane protein with epidermal growth factor-like and
been determined by the Chi-square test or by the Fisher's exact test.
Figure 2. The methylation-speciﬁc polymerase chain reaction results for the random sampling of endometrial cancer (case #15, #51, and #69), hyperplasia of endometrium (case
#6, #83, and #46), and the normal endometrium (case #79 and #83). COL14A1 ¼ collagen type XIV a1; DPYSL4 ¼ dihydropyrimidinase-like 4; HOXA9 ¼ homeobox A9;
H2O ¼ reaction without template DNA; PC ¼ positive control with commercial methylated DNA; NC ¼ negative control with DNA from male whole blood; M ¼ methylation;
TMEFF2 ¼ transmembrane protein with epidermal growth factor-like and two follistatin-like domains 2; U ¼ unmethylation; ZNF177 ¼ zinc ﬁnger protein 177.
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and the clinicopathological parameters of patients with EC. We
found that the methylation of TMEFF2 was higher in well-
differentiated tumors than in moderately or poorly differentiated
tumors (p ¼ 0.0057). Furthermore, no signiﬁcant correlations
existed between the methylation of any gene in regard to age, BMI,
stage, or grade.Figure 3. The sequencing of the methylation-speciﬁc polymerase chain reaction (MS-PCR)
#79), hyperplasia of endometrium (case #6), and endometrial cancer (case #15). The MS-PC
The sequence “TG” in MS-PCR-reverse indicates unmethylation, the sequence “CG” in MS-
polymerase chain reaction; U ¼ unmethylation.Discussion
Endometrial carcinogenesis is a multistep process involving a
precursor lesion with underlying genetic and epigenetic events.
Therefore, molecular diagnostic methods have been proposed as
new ancillary tools for the detection of cancers and for the differ-
ential diagnosis of premalignant and malignant lesions. Anproduct, compared to MS-PCR. The samples are from the normal endometrium (case
R shows full methylation in case #79, and shows hemimethylation in cases #6 and #15.
PCR-reverse indicates methylation. M ¼ methylation; MS-PCR ¼ methylation-speciﬁc
Figure 4. The receiver operating characteristic (ROC) curve analysis of the genes ZNF177, COL14A1, DPYSL4, HOXA9, and TMEFF2. The area under the ROC curve (AUC) of each gene is
calculated for the diagnosis of a normal endometrium and endometrial cancer. AUC ¼ area under the curve; COL14A1 ¼ collagen type XIV a1; DPYSL4 ¼ dihydropyrimidinase-like 4;
HOXA9 ¼ homeobox A9; M ¼ methylation; MSP-F ¼ methylation polymerase chain reaction-forward; MSP-R ¼ methylation polymerase chain reaction-reverse; ROC ¼ receiver
operating characteristic; TMEFF2 ¼ transmembrane protein with epidermal growth factor-like and two follistatin-like domains 2; U ¼ unmethylation; ZNF177 ¼ zinc ﬁnger protein
177.
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EC, based on DNA mismatch repair (MMR) deﬁciency, which is a
typical genetic defect in this cancer [15]. The DNA MMR system
corrects errors in bases that arise when genes are replicated during
cell division. Silencing of the DNAMMR genes reduces the ability to
repair gene mutations. Microsatellite instability (MSI) occurs when
the MMR system is damaged. Abnormalities in the MMR system
may cause replication errors in the repeating unit, leading to
changes in length, which is referred to as MSI. This results in an
accumulation of cancer-related gene mutations and leads tocarcinogenesis, which includes EC [15,16]. The human mutL ho-
molog 1 (hMLH1) gene is a typical gene for MMR that is silenced by
DNA methylation. In EC, hMLH1 silencing occurs in approximately
40% of patients and is an important step in the early stages of
carcinogenesis in which the loss of DNA MMR function may lead to
mutation of genes such as PTEN [15,17].
In our present study, our ﬁve selected genes, ZNF177, COL14A1,
HOXA9, DPYSL4, and TMEFF2, were identiﬁed using the Illumina
Methylation 450K Array System with the analysis of the methyl-
ation differences alone and in combination with independent gene
Table 4
Combined testing of DNA methylation in the detection of endometrial cancer.
Gene set Any one gene (methylated) Both genes (methylated)
Sensitivity (%) Speciﬁcity (%) Sensitivity (%) Speciﬁcity (%)
ZNF177/COL14A1 96.2 88.9 88.5 100
ZNF177/HOXA9 96.2 88.9 76.9 100
ZNF177/TMEFF2 96.2 88.9 61.5 100
COL14A1/HOXA9 96.2 88.9 76.9 100
COL14A1/TMEFF2 96.2 88.9 61.5 100
ZNF177/COL14A1/HOXA9 96.2 83.3 73.1 100
COL14A1¼ collagen type XIV a1;DPYSL4¼ dihydropyrimidinase-like 4;HOXA9¼ homeobox A9; TMEFF2¼ transmembrane protein with epidermal growth factor-like and two
follistatin-like domains 2; ZNF177 ¼ zinc ﬁnger protein 177.
Table 5
The correlation between DNA hypermethylation and the clinicopathological parameters of patients with endometrial cancer.
ZNF177
(MI > 1.533)
COL14A1
(MI > 0.027)
HOXA9
(MI > 1.096)
TMEFF2
(MI > 0.219)
DPYSL4
(MI > 0.091)
U M p U M p U M p U M p U M p
Age (y)
61 1 14 > 0.99 0 15 0.17 3 12 > 0.99 4 11 0.42 5 10 0.69
>61 1 10 2 9 2 9 5 6 5 6
BMI
25.9 2 13 0.49 1 14 > 0.99 4 11 0.36 4 11 0.42 5 10 0.69
>25.9 0 11 1 10 1 10 5 6 5 6
Stage
I þ II 0 19 0.06 1 18 0.47 2 17 0.10 5 14 0.19 7 12 > 0.99
III þ IV 2 5 1 6 3 4 4 3 3 4
Grade
1 0 6 0.13 1 5 0.72 0 6 0.27 0 6 0.0057 3 3 0.58
2 0 9 0 9 3 6 2 7 1 8
3 2 9 1 10 3 8 7 4 6 5
All results were determined by the Chi-square test or by Fisher's exact test.
BMI ¼ body mass index; COL14A1 ¼ collagen type XIV a1; DPYSL4 ¼ dihydropyrimidinase-like 4; HOXA9 ¼ homeobox A9; M ¼ methylation; MI ¼ methylation index;
TMEFF2 ¼ transmembrane protein with epidermal growth factor-like and two follistatin-like domains 2; U ¼ unmethylation; ZNF177 ¼ zinc ﬁnger protein 177.
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ported [18], especially in EC. They are neither MMR genes nor MSI
genes. In patients with EC, we found aberrant hypermethylation of
ZNF177, COL14A1, HOXA9, TMEFF2, and DPYSL4 in 92.3%, 92.3%,
80.8%, 65.4%, and 61.5% of patients, respectively. A signiﬁcant
decrease in gene expression was present in patients with aberrant
methylation of many of these genes (p < 0.01). Aberrant methyl-
ation of TMEFF2 was also present in 50% of patients with hyper-
plasia of the endometrium (p < 0.001). However, very low aberrant
methylation of the ﬁve cancer-related genes was found in patients
with a normal endometrium. These results indicated that the
normal endometrium does not have aberrant methylation of spe-
ciﬁc genes (most frequently ZNF177 and COL14A1) that are associ-
ated with carcinogenesis in EC. The aberrant methylation of TMEFF2
in hyperplasia of the endometrium, which occurs in precancerous
lesions of EC, supports the hypothesis that aberrant methylation of
TMEFF2 is an important event in carcinogenesis in EC.
Endometrial cancer is the most common malignancy of the fe-
male genital tract; however, routine screening is not recom-
mendeddthe rationale being that symptoms due to these
malignancies develop at an early stage in 85% of cases [19e21].
Conventional screening modalities for EC include measuring
endometrial thickness with transvaginal sonography and endo-
metrial sampling with cytological examination. Molecular diag-
nostic methods have been proposed as new ancillary tools for
detecting previously undetected cancers and for the differential
diagnosis of premalignant and malignant lesions. Abnormal pat-
terns of DNA methylation have been recognized in various cancers.
An increase in DNA methylation in gene promoter regions often
precedes apparent malignant changes, which suggests that theassessment of DNA methylation could be used for the early diag-
nosis of cancer [8,12,22]. Our results demonstrate the usefulness of
assessing DNA methylation for detecting EC in endometrial hy-
perplasia. Patients with high methylation levels of TMEFF2 should
receive a thorough assessment, which includes a detailed magnetic
resonance imaging evaluation before any major operation, or they
should be checked by an intraoperative frozen section because
TMEFF2 has a high methylation rate in hyperplasia of the endo-
metrium and in EC.
Despite these promising results, the current study has some
limitations. All patients in the current study were Asian, the sample
size was small, and the cutoff value for each gene was deﬁned by
the criteria of a hospital-based case-controlled study that used a
research platform, which may not be directly applicable to the
clinical setting or to wider populations. The application of these
new biomarkers may provide a new molecular method of man-
agement for ambiguous cases of endometrial sampling and war-
rants further validation in a larger, population-based study. In
addition, the extent to which the current results can be applied to
populations with other ethnicities remains to be determined.
In conclusion, promoter methylation of ZNF177, COL14A1,
HOXA9, DPYSL4, and TMEFF2 is a frequent epigenetic event in EC.
Furthermore, the epigenetic hypermethylation of TMEFF2 is
potentially a valuable marker for identifying undetected EC within
endometrial hyperplasia.Conﬂicts of interest
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